-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 27, 2021, Zhifei Biotech, a large domestic vaccine company, and Fortune 500 global medical technology giant BD Medical signed a strategic cooperation agreement in Chongqing, based on their respective research and development and production of vaccines and prefilling technology and supply of medicines.
The scene of the signing of a strategic cooperation agreement between Zhifei Biotechnology and BD Medical
The scene of the signing of a strategic cooperation agreement between Zhifei Biotechnology and BD MedicalIn response to the "Healthy China 2030" outline, in the process of "strengthening the prevention and control of major infectious diseases" and "continuing the implementation of the expansion of the national immunization plan", the efficiency of the entire process of vaccine production, storage, transportation and inoculation, as well as vaccine accessibility and safety have been improved To meet the needs of the CDC, medical service institutions and the majority of vaccinators is the starting point for the strategic cooperation between the two parties.
Jiang Rensheng, Chairman of Zhifei Biological, made a speech at the signing ceremony
Jiang Rensheng, Chairman of Zhifei Biological, made a speech at the signing ceremonyJiang Rensheng, chairman of Zhifei Biotech, said: “As a vaccine and biological product R&D and manufacturing company, Zhifei Biotech has formed a good cycle mechanism of R&D, market mutual transformation and mutual promotion through the two-wheel drive model of'technology + market', which has accelerated The process of product research and development to the realization of market value conversion has gradually formed a unique core competitiveness.
Deng Jianmin, Senior Vice President of BD Medical Global and General Manager of Greater China Region, delivered a speech at the signing ceremony
Deng Jianmin, Senior Vice President of BD Medical Global and General Manager of Greater China Region, delivered a speech at the signing ceremonyDeng Jianmin, Global Senior Vice President of BD Medical and General Manager of Greater China Region, said at the signing ceremony: “Based on the value orientation of innovative operation management, empowering immune planning, and leading the development of the health industry, this time BD Medical and Zhifei Bio Further expand the results of the cooperation between the two parties; at the same time, BD Medical has always adhered to the concept of "rooted in China, serving China (in china for china)" to provide Chinese pharmaceutical companies with a package that includes the world's most advanced products and a full range of value-added services.
Lu Liang, Vice President of BD Medical China Pharmaceutical System, at the signing ceremony
Lu Liang, Vice President of BD Medical China Pharmaceutical System, at the signing ceremonyAs a business unit serving Chinese pharmaceutical companies, the pharmaceutical system business of BD Biosciences Greater China has been widely recognized by the Chinese pharmaceutical industry.
This time, the two parties reached a comprehensive strategic cooperation on key projects such as Mycobacterium vaccae vaccine (for people infected with tuberculosis), influenza virus split vaccine, 23-valent pneumococcal polysaccharide vaccine, 15-valent pneumococcal conjugate vaccine, and recombinant protein new crown vaccine.